Value of the radiotracer 99mTc-MIP-1404 and of the Anger camera Veriton CZT in patients with prostate cancer.

The value of 99mTc-MIP-1404 SPECT/CT Veriton CZT for staging of prostate cancer and before primary therapy and in biochemical recurrence after radical prostatectomy. Fase II study.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2021-001059-15-SE

Enrollment

250

Registered

2022-02-16

Start date

2022-04-05

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer. Please see the study protocol.

Interventions

Product Name: MIP-5060 kit for radiofarmaceutical preparation of 99mTc-MIP-1404 Pharmaceutical Form: Injection

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Please see the study protocol Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 200

Exclusion criteria

Exclusion criteria: Please see the study protocol´s "inklusion och exklusionskriterier"

Design outcomes

Primary

Measure	Time frame
Main Objective: Please see the study protocol;Secondary Objective: Not applicable;Primary end point(s): Please see the study protocol´s "endpoint";Timepoint(s) of evaluation of this end point: Please see the study protocol´s "tidtabell"	—

Secondary

Measure	Time frame
Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable	—

Countries

Sweden

Contacts

Public ContactNuclear Medicine

Fysiologiska Kliniken

kjell.jansson@regionostergotland.se460101059635

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026